Merck Unit Loses $2.5B Verdict As Hep C Patent Invalidated
A Delaware federal judge dismantled a Merck & Co. unit's $2.5 billion jury verdict win over Gilead Sciences Inc. in an infringement suit over a hepatitis C drug patent, finding Friday...To view the full article, register now.
Already a subscriber? Click here to view full article